MANE Valuation

Veradermics Inc (MANE) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Veradermics Inc (MANE) is between -- to -- according to relative valuation method.

MANE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Veradermics Inc (MANE) is between -- to -- according to relative valuation method.

The average P/S ratio for MANE's competitors is 6.46, providing a benchmark for relative valuation. Veradermics Inc Corp (MANE) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Mar 02 2026, Veradermics Inc (MANE) has a P/B ratio of NaN. This indicates that the market values MANE at NaN times its book value.

As of Mar 02 2026, Veradermics Inc (MANE) has a FCF Yield of NaN%. This means that for every dollar of Veradermics Inc's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 02 2026, Veradermics Inc (MANE) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Veradermics Inc's expected earnings over the next 12 months.

As of Mar 02 2026, Veradermics Inc (MANE) has a Forward P/S ratio of NaN. This means the market is valuing MANE at $NaN for every dollar of expected revenue over the next 12 months.